Sodium Phosphate Shortage: What Providers and Prescribers Need to Know in 2026

Prescribers ordering sodium phosphate, dibasic/sodium phosphate, monobasic (OsmoPrep) for colonoscopy preparation are increasingly reporting that patients are unable to fill their prescriptions in a timely manner. While OsmoPrep is not on the FDA's official Drug Shortage Database as of 2026, localized stocking gaps at retail pharmacies are creating real-world barriers for patients — sometimes leading to colonoscopy delays and rescheduling. This guide provides a clinical framework for managing these challenges.

Current Availability Status: Oral vs. IV Sodium Phosphate

There are two distinct clinical uses of sodium phosphate that providers must track separately:

Oral sodium phosphate tablets (OsmoPrep): FDA-approved for colon cleansing prior to colonoscopy in adults. Not currently listed as an FDA shortage. However, stocking is inconsistent across retail pharmacy networks, with brand-name availability varying significantly by geography and pharmacy type.

IV sodium phosphate (Hospira/American Regent): Used in inpatient and TPN settings to prevent or correct hypophosphatemia. Has historically experienced supply disruptions. Hospital pharmacists should verify current stock through GPO channels and consider potassium phosphate as an alternative for TPN formulations when indicated.

The Boxed Warning: What Every Prescriber Must Know

OsmoPrep carries a boxed warning for acute phosphate nephropathy (APN) — a rare but potentially irreversible form of kidney injury caused by calcium-phosphate precipitation in renal tubules. The FDA required this warning in December 2008 after reports of permanent renal impairment, including patients requiring long-term dialysis. Key prescribing considerations:

APN can occur even in patients without identifiable risk factors

Onset is typically within days post-ingestion, but can be delayed up to several months

OsmoPrep should NOT be administered within 7 days of previous use

Electrolyte and fluid abnormalities must be corrected before initiating prep

Patient Risk Stratification: Who Should NOT Receive OsmoPrep

OsmoPrep is contraindicated or requires extreme caution in the following patient populations:

Absolute contraindications: Prior acute phosphate nephropathy, bowel obstruction or perforation, toxic megacolon, toxic colitis, gastric bypass/stapling surgery, hypersensitivity to sodium phosphate

High-risk groups requiring alternative prep: CKD (any stage), heart failure, dehydration or hypovolemia, active colitis or IBD flare, age >55 (especially with CKD), patients on ACE inhibitors, ARBs, diuretics, or NSAIDs

Use with caution and close monitoring: Prolonged QT interval, arrhythmia history, alcohol or benzodiazepine withdrawal

Evidence-Based Alternatives for Colonoscopy Preparation

For patients who cannot use OsmoPrep, or when it is unavailable, the following alternatives have strong evidence for efficacy and safety:

PEG-based preps (GoLYTELY, NuLYTELY, GaviLyte): First-line for CKD, heart failure, elderly patients. Minimal electrolyte shifts. Large volume (4L) is the primary tolerability concern. Generic cost is very low ($5–15 with coupons).

Low-volume PEG + ascorbate (MoviPrep, Plenvu): Improved tolerability at 2L; high efficacy in RCTs; avoid in patients with G6PD deficiency (ascorbate component).

SUTAB (sodium sulfate tablets): FDA-approved 2020. Noninferior to MoviPrep in the pivotal trial (92% adequate prep rate). No APN risk. Preferred for patients who want tablet convenience without sodium phosphate's renal risks.

Suprep (sodium/potassium/magnesium sulfate): Lower volume than GoLYTELY; no phosphate nephropathy risk; well-tolerated; widely available.

Clenpiq (sodium picosulfate + magnesium oxide + citric acid): Very low volume (two 160-mL bottles). Good tolerability. Avoid in severe renal impairment (eGFR <30).

MiraLAX + bisacodyl (OTC combination): Not FDA-approved for colonoscopy prep but widely used in clinical practice. Good tolerability; minimal electrolyte shifts; lowest cost option. Advise patients specifically on bisacodyl dosing and prep timing.

Prescribing Workflow Recommendations for Your Practice

Establish a preferred pharmacy partner: Work with a local pharmacy (ideally your hospital's outpatient pharmacy or a nearby independent) that reliably stocks your preferred preps. Alert patients to use this pharmacy rather than their usual chain.

Screen patients before writing OsmoPrep: Use a brief intake questionnaire or EHR alert flagging contraindicated conditions (CKD, heart failure, age >55 on nephrotoxic meds) to route those patients directly to PEG or sulfate-based alternatives.

Send the prescription early: Advise patients to fill prescriptions at least 5–7 days before their prep day to allow time for sourcing if needed.

Use medfinder for patients who can't find it: Refer patients to medfinder.com/providers for assistance locating their prescribed prep near them quickly.

Managing IV Sodium Phosphate Supply in Clinical Settings

For hospitalists and critical care teams managing IV sodium phosphate for hypophosphatemia or TPN supplementation, the following considerations apply during periods of constrained supply:

Potassium phosphate IV is therapeutically equivalent in most patients and may be substituted when sodium load is not a concern

Monitor sodium levels carefully when using sodium phosphate in patients with edema, heart failure, or hypernatremia risk

Each 1 mmol of phosphate in the IV form contains approximately 1.3 mEq of sodium — account for this in total electrolyte calculations

For a practical guide on helping your patients locate their prescribed prep, see how to help your patients find sodium phosphate in stock. You can also direct patients to medfinder for providers for a coordinated approach.